Guisier et al. had determined immune checkpoint inhibitors (ICIs) effectiveness in NSCLC patients harbouring BRAF, HER2, MET, and RET genes abnormalities in a real-world setting. Here, BRAF is linked to non-small cell lung carcinoma.